首页 > 最新文献

Recent patents on inflammation & allergy drug discovery最新文献

英文 中文
Acute Myocarditis in Children: An Overview of Treatment and Recent Patents. 儿童急性心肌炎:治疗综述及近期专利。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14666200204103714
Ronald C M Fung, Kam L Hon, Alexander K C Leung

Background: Pediatric myocarditis is rare but challenging. This overview summarized the current knowledge and recent patents on childhood myocarditis.

Methods: Clinical queries and keywords of "myocarditis" and "childhood" were used as search engine.

Results: Viral infections are the most common causes of acute myocarditis. Affected children often have a prodrome of fever, malaise, and myalgia. Clinical manifestations of acute myocarditis in children can be nonspecific. Some children may present with easy fatigability, poor appetite, vomiting, abdominal pain, exercise intolerance, respiratory distress/tachypnea, dyspnea at rest, orthopnea, chronic cough with wheezing, chest pain, unexplained tachycardia, hypotension, syncope, and hepatomegaly. Supraventricular arrhythmias, ventricular arrhythmias, and heart block may be present. A subset of patients have fulminant myocarditis and present with cardiovascular collapse, which may progress to severe cardiogenic shock, and even death. A high index of suspicion is crucial to its diagnosis and timely management. Cardiac magnetic resonance imaging is important in aiding clinical diagnosis while, endomyocardial biopsy remains the gold standard. The treatment consists of supportive therapy, ranging from supplemental oxygen and fluid restriction to mechanical circulatory support. Angiotensinconverting enzyme inhibitors, angio-tensin II receptor blockers, β-blockers, and aldosterone antagonists might be used for the treatment of heart failure while, immunosuppression treatments remain controversial. There are a few recent patents targeting prevention or treatment of viral myocarditis, including an immunogenic composition comprising a PCV-2 antigen, glutathione-S-transferase P1, neuregulins, NF-[kappa] B inhibitor, a pharmaceutical composition which contains 2-amino-2- (2- (4-octyl phenyl) - ethyl) propane 1,3-diol, a composition containing pycnojenol, Chinese herbal concoctions, and a Korean oral rapamycin. Evidence of their efficacy is still lacking.

Conclusion: This article reviews the current literature regarding etiology, clinical manifestations, diagnosis, and management of acute myocarditis in children.

背景:小儿心肌炎是一种罕见但具有挑战性的疾病。本文综述了目前关于儿童心肌炎的知识和最新专利。方法:以“心肌炎”、“儿童期”的临床查询及关键词为搜索引擎。结果:病毒性感染是急性心肌炎最常见的病因。患病儿童通常有发热、不适和肌痛的前驱症状。儿童急性心肌炎的临床表现可以是非特异性的。部分患儿可表现为易疲劳、食欲不振、呕吐、腹痛、运动不耐受、呼吸窘迫/呼吸急促、休息时呼吸困难、矫形呼吸、慢性咳嗽伴喘息、胸痛、不明原因的心动过速、低血压、晕厥和肝肿大。可能出现室上性心律失常、室性心律失常和心脏传导阻滞。一部分患者有暴发性心肌炎并表现为心血管衰竭,这可能发展为严重的心源性休克,甚至死亡。高怀疑指数对其诊断和及时治疗至关重要。心脏磁共振成像在辅助临床诊断中很重要,而心内膜活检仍然是金标准。治疗包括支持治疗,从补充氧气和液体限制到机械循环支持。血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、β阻滞剂和醛固酮拮抗剂可用于治疗心力衰竭,而免疫抑制治疗仍有争议。最近有一些针对预防或治疗病毒性心肌炎的专利,包括一种含有PCV-2抗原、谷胱甘肽- s -转移酶P1、神经调节蛋白、NF-[kappa] B抑制剂的免疫原性组合物,一种含有2-氨基-2-(2-(4-辛基苯基)-乙基)丙烷1,3-二醇的药物组合物,一种含有吡诺酚的组合物,中草药混合物,以及一种韩国口服雷帕霉素。目前仍缺乏其有效性的证据。结论:本文综述了儿童急性心肌炎的病因、临床表现、诊断和治疗方面的文献。
{"title":"Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.","authors":"Ronald C M Fung,&nbsp;Kam L Hon,&nbsp;Alexander K C Leung","doi":"10.2174/1872213X14666200204103714","DOIUrl":"https://doi.org/10.2174/1872213X14666200204103714","url":null,"abstract":"<p><strong>Background: </strong>Pediatric myocarditis is rare but challenging. This overview summarized the current knowledge and recent patents on childhood myocarditis.</p><p><strong>Methods: </strong>Clinical queries and keywords of \"myocarditis\" and \"childhood\" were used as search engine.</p><p><strong>Results: </strong>Viral infections are the most common causes of acute myocarditis. Affected children often have a prodrome of fever, malaise, and myalgia. Clinical manifestations of acute myocarditis in children can be nonspecific. Some children may present with easy fatigability, poor appetite, vomiting, abdominal pain, exercise intolerance, respiratory distress/tachypnea, dyspnea at rest, orthopnea, chronic cough with wheezing, chest pain, unexplained tachycardia, hypotension, syncope, and hepatomegaly. Supraventricular arrhythmias, ventricular arrhythmias, and heart block may be present. A subset of patients have fulminant myocarditis and present with cardiovascular collapse, which may progress to severe cardiogenic shock, and even death. A high index of suspicion is crucial to its diagnosis and timely management. Cardiac magnetic resonance imaging is important in aiding clinical diagnosis while, endomyocardial biopsy remains the gold standard. The treatment consists of supportive therapy, ranging from supplemental oxygen and fluid restriction to mechanical circulatory support. Angiotensinconverting enzyme inhibitors, angio-tensin II receptor blockers, β-blockers, and aldosterone antagonists might be used for the treatment of heart failure while, immunosuppression treatments remain controversial. There are a few recent patents targeting prevention or treatment of viral myocarditis, including an immunogenic composition comprising a PCV-2 antigen, glutathione-S-transferase P1, neuregulins, NF-[kappa] B inhibitor, a pharmaceutical composition which contains 2-amino-2- (2- (4-octyl phenyl) - ethyl) propane 1,3-diol, a composition containing pycnojenol, Chinese herbal concoctions, and a Korean oral rapamycin. Evidence of their efficacy is still lacking.</p><p><strong>Conclusion: </strong>This article reviews the current literature regarding etiology, clinical manifestations, diagnosis, and management of acute myocarditis in children.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"106-116"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37606321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents. 儿童斑秃:治疗综述及近期专利。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14999200728145822
Kam L Hon, David C K Luk, Alexander K C Leung, Chantel Ng, Steven K F Loo
BACKGROUNDAlopecia Areata (AA) is a systemic autoimmune condition which usually starts in childhood.OBJECTIVEThis article aims to review genetics, therapy, prognosis and recent patents for AA.METHODSWe used clinical queries and keywords of "alopecia areata" AND "childhood" as search engine. Patents were searched using the key term "alopecia areata" in Patents.google.com and freepatentsonline.com.RESULTSDue to an immune mediated damage of the hair follicles, hair is lost from the scalp and other areas of the body temporarily or even permanently. Children with AA are generally healthy. Evidence of genetic association and increased predisposition for AA was found by studying families with affected members. Pathophysiologically, T- lymphocytes attack hair follicles and cause inflammation and destruction of the hair follicles and hair loss. In mild cases, there would be well demarcated round patchy scalp hair loss. The pathognomonic "exclamation mark hairs" may be seen at lesion periphery. In more severe cases, the hair loss may affect the whole scalp and even the whole body. The clinical course is also variable which may range from transient episodes of recurrent patchy hair loss to an indolent gradually deteriorating severe hair loss. The treatment of AA depends on factors including patients' age, extent of the hair loss, duration of disease, psychological impact, availability and side effect profile of the treatments. For localized patchy alopecia, topical application of corticosteroids and/or intralesional corticosteroids are the treatment of choice. Other topical treatments include minoxidil, anthralin, coal tar and immunotherapy. In severe resistant cases, systemic immunosuppressants may be considered. Although herbal medicine, acupuncture, complementary and alternative medicine may be tried on children in some Asian communities, the evidence to support these practices are lacking. To date, only few recent patents exist in topical treatments including Il-31, laser and herbal medications. Clinical efficacy is pending for these treatment modalities.CONCLUSIONSNone of the established therapeutic options are curative. However, newer treatment modalities including excimer laser, interleukin-31 antibodies and biologics are evolving so that there may be significant advances in treatment in the near future. AA can be psychosocially devastating. It is important to assess the quality of life, degree of anxiety, social phobia and mood of the patients and their families. Psychological support is imperative for those who are adversely affected psychosocially.
背景:斑秃(AA)是一种全身性自身免疫性疾病,通常开始于儿童时期。目的:综述AA的遗传学、治疗、预后及近期专利。方法:以临床查询和关键词“斑秃”、“童年”为搜索引擎。在Patents.google.com和frepatentsonline上以“斑秃”为关键词搜索专利。com。结果:由于免疫介导的毛囊损伤,头发会从头皮和身体其他部位暂时甚至永久性地脱落。嗜酒成瘾的儿童通常是健康的。通过研究有AA患者的家庭,发现了遗传关联和增加AA易感性的证据。病理生理上,T淋巴细胞攻击毛囊,引起炎症和破坏毛囊和脱发。在轻微的情况下,会有明确划分的圆形斑驳头皮脱发。病变周围可见典型的“感叹号毛”。在更严重的情况下,脱发可能会影响整个头皮甚至整个身体。临床过程也是多变的,其范围可以从短暂的复发性斑状脱发到逐渐恶化的惰性严重脱发。AA的治疗取决于患者的年龄、脱发程度、疾病持续时间、心理影响、治疗的可用性和副作用等因素。对于局部斑秃,局部应用皮质类固醇和/或局部皮质类固醇是治疗的选择。其他局部治疗包括米诺地尔、炭疽病、煤焦油和免疫疗法。在严重耐药病例中,可以考虑使用全身免疫抑制剂。虽然一些亚洲社区的儿童可以尝试使用草药、针灸、补充和替代医学,但缺乏支持这些做法的证据。到目前为止,只有一些最近的专利存在于局部治疗,包括Il-31,激光和草药。这些治疗方式的临床疗效尚待确定。结论:现有的治疗方案均无疗效。然而,新的治疗方式,包括准分子激光、白介素-31抗体和生物制剂,正在不断发展,因此在不久的将来可能会有重大的治疗进展。嗜酒者互戒会对心理社会造成毁灭性的影响。重要的是评估患者及其家属的生活质量、焦虑程度、社交恐惧症和情绪。心理支持对于那些受到不良社会心理影响的人来说是必不可少的。
{"title":"Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.","authors":"Kam L Hon,&nbsp;David C K Luk,&nbsp;Alexander K C Leung,&nbsp;Chantel Ng,&nbsp;Steven K F Loo","doi":"10.2174/1872213X14999200728145822","DOIUrl":"https://doi.org/10.2174/1872213X14999200728145822","url":null,"abstract":"BACKGROUND\u0000Alopecia Areata (AA) is a systemic autoimmune condition which usually starts in childhood.\u0000\u0000\u0000OBJECTIVE\u0000This article aims to review genetics, therapy, prognosis and recent patents for AA.\u0000\u0000\u0000METHODS\u0000We used clinical queries and keywords of \"alopecia areata\" AND \"childhood\" as search engine. Patents were searched using the key term \"alopecia areata\" in Patents.google.com and freepatentsonline.com.\u0000\u0000\u0000RESULTS\u0000Due to an immune mediated damage of the hair follicles, hair is lost from the scalp and other areas of the body temporarily or even permanently. Children with AA are generally healthy. Evidence of genetic association and increased predisposition for AA was found by studying families with affected members. Pathophysiologically, T- lymphocytes attack hair follicles and cause inflammation and destruction of the hair follicles and hair loss. In mild cases, there would be well demarcated round patchy scalp hair loss. The pathognomonic \"exclamation mark hairs\" may be seen at lesion periphery. In more severe cases, the hair loss may affect the whole scalp and even the whole body. The clinical course is also variable which may range from transient episodes of recurrent patchy hair loss to an indolent gradually deteriorating severe hair loss. The treatment of AA depends on factors including patients' age, extent of the hair loss, duration of disease, psychological impact, availability and side effect profile of the treatments. For localized patchy alopecia, topical application of corticosteroids and/or intralesional corticosteroids are the treatment of choice. Other topical treatments include minoxidil, anthralin, coal tar and immunotherapy. In severe resistant cases, systemic immunosuppressants may be considered. Although herbal medicine, acupuncture, complementary and alternative medicine may be tried on children in some Asian communities, the evidence to support these practices are lacking. To date, only few recent patents exist in topical treatments including Il-31, laser and herbal medications. Clinical efficacy is pending for these treatment modalities.\u0000\u0000\u0000CONCLUSIONS\u0000None of the established therapeutic options are curative. However, newer treatment modalities including excimer laser, interleukin-31 antibodies and biologics are evolving so that there may be significant advances in treatment in the near future. AA can be psychosocially devastating. It is important to assess the quality of life, degree of anxiety, social phobia and mood of the patients and their families. Psychological support is imperative for those who are adversely affected psychosocially.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"117-132"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38210829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases. 白三烯抑制剂在慢性炎性疾病治疗中的作用
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14666200130095040
Deepak Meshram, Khushbo Bhardwaj, Charulata Rathod, Gail B Mahady, Kapil K Soni

Background: Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion.

Objectives: To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.

Methods: Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study.

Results: Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases.

Conclusion: The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.

背景:白三烯是一种强大的炎症介质,可与靶细胞膜上的特定受体相互作用,从而引发炎症反应。因此,白三烯(lt)被认为是炎症性疾病的有效介质,包括过敏性鼻炎、炎症性肠病和哮喘。白三烯B4和一系列半胱氨酸白三烯(C4、D4和E4)是花生四烯酸代谢的代谢物,引起炎症。已知半胱氨酸LTs可增加血管通透性、支气管收缩和粘液分泌。目的:回顾植物来源的白三烯抑制剂的已发表数据和最近的白三烯抑制剂专利,以及它们在炎症性疾病管理中的作用。方法:检索1938年至2019年已发表的植物来源白三烯拮抗剂的数据,不受语言限制,使用自由文本和医学主题词(MeSH terms)格式的相关关键词。通过Science Direct、PubMed、MEDLINE、Google Patents、US Patents、US patent Applications、Abstract of Japan、German Patents、European Patents、WIPO和NAPRALERT等科学数据库对白三烯抑制剂领域的文献和专利进行检索。最后,本研究对这些信息资源的数据进行分析和报告。结果:目前,抗组胺药物有很多,包括氯苯那明、溴苯那明、西替利嗪和克莱门汀。此外,来自对抗性药物的特异性白三烯拮抗剂也可用,包括zileuton、孟鲁司特、pranlukast和zafirlukast,与第一代药物相比,它们被认为是有效和安全的药物。本研究报告了白三烯拮抗剂的天然产物和某些最近的专利,可能是在呼吸道疾病的炎症管理的替代药物。结论:本研究重点介绍了白三烯拮抗剂在炎症性呼吸道疾病治疗中的药理学和专利的最新进展。
{"title":"The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases.","authors":"Deepak Meshram,&nbsp;Khushbo Bhardwaj,&nbsp;Charulata Rathod,&nbsp;Gail B Mahady,&nbsp;Kapil K Soni","doi":"10.2174/1872213X14666200130095040","DOIUrl":"https://doi.org/10.2174/1872213X14666200130095040","url":null,"abstract":"<p><strong>Background: </strong>Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion.</p><p><strong>Objectives: </strong>To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.</p><p><strong>Methods: </strong>Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study.</p><p><strong>Results: </strong>Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases.</p><p><strong>Conclusion: </strong>The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"15-31"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37593537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Nummular Eczema: An Updated Review. numular湿疹:最新综述。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14666200810152246
Alexander K C Leung, Joseph M Lam, Kin Fon Leong, Amy A M Leung, Alex H C Wong, Kam L Hon

Background: Nummular eczema may mimic diseases that present with annular configuration and the differential diagnosis is broad.

Objective: This article aimed to provide an update on the evaluation, diagnosis, and treatment of nummular eczema.

Methods: A PubMed search was performed in using the key terms "nummular eczema", "discoid eczema", OR "nummular dermatitis". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. The information retrieved from the above search was used in the compilation of the present article. Patents were searched using the key terms "nummular eczema", "discoid eczema", OR "nummular dermatitis" in www.google.com/patents and www.freepatentsonline.com.

Results: Nummular eczema is characterized by sharply defined, oval or coin-shaped, erythematous, eczematous plaques. Typically, the size of the lesion varies from 1 to 10cm in diameter. The lesions are usually multiple and symmetrically distributed. Sites of predilection include the lower limbs followed by the upper limbs. The lesions are usually intensely pruritic. The diagnosis is mainly clinical based on the characteristic round to oval erythematous plaques in a patient with diffusely dry skin. Nummular eczema should be distinguished from other annular lesions. Dermoscopy can reveal additional features that can be valuable for correct diagnosis. Biopsy or laboratory tests are generally not necessary. However, a potassium hydroxide wet-mount examination of skin scrapings should be performed if tinea corporis is suspected. Because contact allergy is common with nummular eczema, patch testing should be considered in patients with chronic, recalcitrant nummular eczema. Avoidance of precipitating factors, optimal skin care, and high or ultra-high potency topical corticosteroids are the mainstay of therapy. Recent patents related to the management of nummular eczema are also discussed.

Conclusion: With proper treatment, nummular eczema can be cleared over a few weeks, although the course can be chronic and characterized by relapses and remissions. Moisturizing of the skin and avoidance of identifiable exacerbating factors, such as hot water baths and harsh soaps may reduce the frequency of recurrence. Diseases that present with annular lesions may mimic nummular eczema and the differential diagnosis is broad. As such, physicians must be familiar with this condition so that an accurate diagnosis can be made, and appropriate treatment initiated.

背景:钱币状湿疹可能与环状结构的疾病相似,鉴别诊断广泛。目的:本文旨在提供最新的评估,诊断和治疗钱币湿疹。方法:以“钱币状湿疹”、“盘状湿疹”或“钱币状皮炎”为关键词进行PubMed检索。检索策略包括荟萃分析、随机对照试验、临床试验、观察性研究和综述。搜索仅限于英国文学。从上述搜索中检索到的信息用于编写本文。在www.google.com/patents和www.freepatentsonline.com.Results中使用关键词“钱币状湿疹”、“盘状湿疹”或“钱币状皮炎”进行专利检索:钱币状湿疹的特征是轮廓分明、椭圆形或硬币形、红斑、湿疹斑块。通常,病变的大小在直径1到10cm之间。病变通常为多发且对称分布。偏爱的部位包括下肢,其次是上肢。病变通常有强烈的瘙痒感。临床诊断主要基于弥漫性皮肤干燥患者的圆形至椭圆形红斑斑块的特征。钱币状湿疹应与其他环状病变区分开来。皮肤镜检查可以显示对正确诊断有价值的其他特征。通常不需要活检或实验室检查。然而,如果怀疑有体癣,则应对皮肤刮痕进行氢氧化钾湿法检查。因为接触性过敏在钱币性湿疹中很常见,对于慢性顽固性钱币性湿疹患者应考虑进行斑贴试验。避免沉淀因素,最佳的皮肤护理和高或超高效能的局部皮质类固醇是主要的治疗方法。最近的专利有关管理钱币湿疹也进行了讨论。结论:通过适当的治疗,钱币湿疹可以在几周内清除,尽管过程可能是慢性的,并以复发和缓解为特征。皮肤保湿和避免可识别的加重因素,如热水浴和刺激性肥皂可以减少复发的频率。出现环状病变的疾病可能类似于钱币性湿疹,鉴别诊断很广泛。因此,医生必须熟悉这种情况,以便做出准确的诊断,并开始适当的治疗。
{"title":"Nummular Eczema: An Updated Review.","authors":"Alexander K C Leung,&nbsp;Joseph M Lam,&nbsp;Kin Fon Leong,&nbsp;Amy A M Leung,&nbsp;Alex H C Wong,&nbsp;Kam L Hon","doi":"10.2174/1872213X14666200810152246","DOIUrl":"https://doi.org/10.2174/1872213X14666200810152246","url":null,"abstract":"<p><strong>Background: </strong>Nummular eczema may mimic diseases that present with annular configuration and the differential diagnosis is broad.</p><p><strong>Objective: </strong>This article aimed to provide an update on the evaluation, diagnosis, and treatment of nummular eczema.</p><p><strong>Methods: </strong>A PubMed search was performed in using the key terms \"nummular eczema\", \"discoid eczema\", OR \"nummular dermatitis\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. The information retrieved from the above search was used in the compilation of the present article. Patents were searched using the key terms \"nummular eczema\", \"discoid eczema\", OR \"nummular dermatitis\" in www.google.com/patents and www.freepatentsonline.com.</p><p><strong>Results: </strong>Nummular eczema is characterized by sharply defined, oval or coin-shaped, erythematous, eczematous plaques. Typically, the size of the lesion varies from 1 to 10cm in diameter. The lesions are usually multiple and symmetrically distributed. Sites of predilection include the lower limbs followed by the upper limbs. The lesions are usually intensely pruritic. The diagnosis is mainly clinical based on the characteristic round to oval erythematous plaques in a patient with diffusely dry skin. Nummular eczema should be distinguished from other annular lesions. Dermoscopy can reveal additional features that can be valuable for correct diagnosis. Biopsy or laboratory tests are generally not necessary. However, a potassium hydroxide wet-mount examination of skin scrapings should be performed if tinea corporis is suspected. Because contact allergy is common with nummular eczema, patch testing should be considered in patients with chronic, recalcitrant nummular eczema. Avoidance of precipitating factors, optimal skin care, and high or ultra-high potency topical corticosteroids are the mainstay of therapy. Recent patents related to the management of nummular eczema are also discussed.</p><p><strong>Conclusion: </strong>With proper treatment, nummular eczema can be cleared over a few weeks, although the course can be chronic and characterized by relapses and remissions. Moisturizing of the skin and avoidance of identifiable exacerbating factors, such as hot water baths and harsh soaps may reduce the frequency of recurrence. Diseases that present with annular lesions may mimic nummular eczema and the differential diagnosis is broad. As such, physicians must be familiar with this condition so that an accurate diagnosis can be made, and appropriate treatment initiated.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"146-155"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38248382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles. 阿司匹林包裹固体脂质微粒的抗炎和胃保护特性。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14666200108101548
Salome A Chime, Paul A Akpa, Cosmas C Ugwuanyi, Anthony A Attama

Background: Aspirin is a nonsteroidal anti-inflammatory drug that is very effective in the treatment of inflammation and other health conditions, however, it causes gastric irritation. Recently, researchers have developed patents (US9757529, 2019) of inhalable aspirin for rapid absorption and circumvention of gastric irritation.

Objective: The aim of this work was to formulate aspirin-loaded lipid based formulation in order to enhance oral bioavailability and inhibit gastric irritation.

Methods: This solid lipid microparticles loaded with aspirin (SLM) was formulated by a modified cold homogenization-solvent evaporation method. In vitro studies such as in vitro drug release, particle size, Encapsulation Efficiency (EE), micromeritic properties and loading capacity were carried out. Pharmacodynamics studies such as anti-inflammatory and ulcerative properties of the SLM were also carried out in Wistar rats.

Results: The results showed that aspirin entrapped SLM exhibited the highest EE of 72% and particle size range of 7.60 + 0.141µm to 20.25 + 0.070µm. Formulations had about 55% drug release at 6h in simulated intestinal fluid pH 6.8. The formulations had good flowability that could facilitate filling into hard gelatin capsule shells. The SLM exhibited 100% gastroprotection against aspirin-induced ulcers (p < 0.05). The percentage of anti-inflammatory activities also showed that aspirin-entrapped SLM had 78% oedema inhibition at 7h, while the reference had 68% inhibition at 7h.

Conclusion: Aspirin-entrapped SLM showed good sustained-release properties, enhanced antiinflammatory properties and total gastric protection from aspirin-induced ulcers and could be used as once-daily oral aspirin.

背景:阿司匹林是一种非甾体抗炎药,在治疗炎症和其他健康状况方面非常有效,然而,它会引起胃刺激。最近,研究人员开发了可吸入阿司匹林的专利(US9757529, 2019),用于快速吸收和规避胃刺激。目的:制备阿斯匹林脂基制剂,提高口服生物利用度,抑制胃刺激。方法:采用改进的冷均质-溶剂蒸发法制备阿司匹林固体脂质微粒。对其体外释放度、粒径、包封效率(EE)、微粒性能和载药量等进行了体外研究。在Wistar大鼠身上进行了抗炎和溃疡特性等药效学研究。结果:阿司匹林包埋的SLM的EE最高,达72%,粒径范围为7.60 + 0.141µm ~ 20.25 + 0.070µm。在pH值为6.8的模拟肠液中,制剂在6h时的释药率约为55%。该配方具有良好的流动性,易于填充到硬明胶胶囊壳中。SLM对阿司匹林引起的溃疡有100%的胃保护作用(p < 0.05)。抗炎活性的百分比也表明,阿司匹林包埋的SLM在7h时的水肿抑制率为78%,而参考文献在7h时的抑制率为68%。结论:阿司匹林包埋SLM具有良好的缓释特性、增强的抗炎特性和对阿司匹林致溃疡的全胃保护作用,可作为阿司匹林每日一次口服。
{"title":"Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles.","authors":"Salome A Chime,&nbsp;Paul A Akpa,&nbsp;Cosmas C Ugwuanyi,&nbsp;Anthony A Attama","doi":"10.2174/1872213X14666200108101548","DOIUrl":"https://doi.org/10.2174/1872213X14666200108101548","url":null,"abstract":"<p><strong>Background: </strong>Aspirin is a nonsteroidal anti-inflammatory drug that is very effective in the treatment of inflammation and other health conditions, however, it causes gastric irritation. Recently, researchers have developed patents (US9757529, 2019) of inhalable aspirin for rapid absorption and circumvention of gastric irritation.</p><p><strong>Objective: </strong>The aim of this work was to formulate aspirin-loaded lipid based formulation in order to enhance oral bioavailability and inhibit gastric irritation.</p><p><strong>Methods: </strong>This solid lipid microparticles loaded with aspirin (SLM) was formulated by a modified cold homogenization-solvent evaporation method. In vitro studies such as in vitro drug release, particle size, Encapsulation Efficiency (EE), micromeritic properties and loading capacity were carried out. Pharmacodynamics studies such as anti-inflammatory and ulcerative properties of the SLM were also carried out in Wistar rats.</p><p><strong>Results: </strong>The results showed that aspirin entrapped SLM exhibited the highest EE of 72% and particle size range of 7.60 + 0.141µm to 20.25 + 0.070µm. Formulations had about 55% drug release at 6h in simulated intestinal fluid pH 6.8. The formulations had good flowability that could facilitate filling into hard gelatin capsule shells. The SLM exhibited 100% gastroprotection against aspirin-induced ulcers (p < 0.05). The percentage of anti-inflammatory activities also showed that aspirin-entrapped SLM had 78% oedema inhibition at 7h, while the reference had 68% inhibition at 7h.</p><p><strong>Conclusion: </strong>Aspirin-entrapped SLM showed good sustained-release properties, enhanced antiinflammatory properties and total gastric protection from aspirin-induced ulcers and could be used as once-daily oral aspirin.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"78-88"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213X14666200108101548","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37521533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Human Ascariasis: An Updated Review. 人类蛔虫病:最新综述。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.2174/1872213X14666200705235757
Alexander K C Leung, Amy A M Leung, Alex H C Wong, Kam L Hon

Background: Ascaris lumbricoides is the most common helminthic infection. More than 1.2 billion people have ascariasis worldwide.

Objective: This article aimed to provide an update on the evaluation, diagnosis, and treatment of ascariasis.

Methods: A PubMed search was conducted in February 2020 in Clinical Queries using the key terms "ascariasis" OR "Ascaris lumbricoides". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews published within the past 10 years. The search was restricted to English literature. The information retrieved from the above search was used in the compilation of the present article. Patents were searched using the key term "ascariasis" OR "Ascaris lumbricoides" in www.freepatentsonline.com.

Results: Ascaris lumbricoides is transmitted through the ingestion of embryonated eggs from fecal- contaminated material. Ascariasis has high endemicity in tropical and subtropical areas. Predisposing factors include poverty, poor sanitation, inadequate sewage disposal, and poor personal hygiene. The prevalence is greatest in children younger than 5 years of age. The majority of patients with intestinal ascariasis are asymptomatic. For those with symptoms, anorexia, nausea, bloating, abdominal discomfort, recurrent abdominal pain, abdominal distension, and intermittent diarrhea are not uncommon. Other clinical manifestations vary widely, depending on the underlying complications. Complications include Löeffler syndrome, intestinal obstruction, biliary colic, recurrent pyogenic cholangitis, cholecystitis, acalculous cholecystitis, obstructive jaundice, cholelithiasis, pancreatitis, and malnutrition. The diagnosis is best established by microscopic examination of fecal smears or following concentration techniques for the characteristic ova. Patients with A. lumbricoides infection warrant anthelminthic treatment, even if they are asymptomatic, to prevent complications from migration of the parasite. Albendazole and mebendazole are the drugs of choice for children and nonpregnant individuals with ascariasis. Pregnant women with ascariasis should be treated with pyrantel pamoate. Recent patents related to the management of ascariasis are also discussed.

Conclusion: The average cure rate with anthelminthic treatment is over 95%. Unfortunately, most treated patients in endemic areas become re-infected within months. Health education, personal hygiene, improved sanitary conditions, proper disposal of human excreta, and discontinuing the use of human fecal matter as a fertilizer are effective long-term preventive measures. Targeting deworming treatment and mass anthelminthic treatment should be considered in regions where A. lumbricoides is prevalent.

背景:类蚓蛔虫是最常见的寄生虫感染。全世界有超过12亿人患有蛔虫病。目的:本文旨在提供蛔虫病的评估、诊断和治疗的最新进展。方法:于2020年2月在“临床查询”中检索PubMed,关键词为“蛔虫病”或“蛔虫”。检索策略包括荟萃分析、随机对照试验、临床试验、观察性研究和过去10年内发表的综述。搜索仅限于英国文学。从上述搜索中检索到的信息用于编写本文。在www.freepatentsonline.com.Results中使用关键词“蛔虫病”或“类蛔虫”进行专利检索:类蛔虫通过摄入受粪便污染物质的胚胎卵传播。蛔虫病在热带和亚热带地区有很高的地方性。诱发因素包括贫困、卫生条件差、污水处理不足和个人卫生状况差。患病率在5岁以下儿童中最高。大多数肠蛔虫病患者无症状。对于那些有症状的人,厌食、恶心、腹胀、腹部不适、反复腹痛、腹胀和间歇性腹泻并不罕见。其他临床表现差异很大,取决于潜在的并发症。并发症包括Löeffler综合征、肠梗阻、胆道绞痛、复发性化脓性胆管炎、胆囊炎、结石性胆囊炎、梗阻性黄疸、胆石症、胰腺炎和营养不良。诊断最好通过粪便涂片的显微镜检查或以下特征性卵子的浓缩技术来确定。即使无症状,蛔虫感染患者也需要驱虫治疗,以防止寄生虫迁移引起的并发症。阿苯达唑和甲苯达唑是儿童和非孕妇蛔虫病患者的首选药物。患有蛔虫病的孕妇应使用吡喃酯治疗。还讨论了与蛔虫病管理有关的最新专利。结论:采用驱虫药治疗,平均治愈率达95%以上。不幸的是,流行地区大多数接受治疗的患者在几个月内再次感染。健康教育、个人卫生、改善卫生条件、妥善处理人类排泄物和停止使用人类排泄物作为肥料是有效的长期预防措施。在蚓类蠓流行的地区,应考虑进行定向驱虫和大规模驱虫。
{"title":"Human Ascariasis: An Updated Review.","authors":"Alexander K C Leung,&nbsp;Amy A M Leung,&nbsp;Alex H C Wong,&nbsp;Kam L Hon","doi":"10.2174/1872213X14666200705235757","DOIUrl":"https://doi.org/10.2174/1872213X14666200705235757","url":null,"abstract":"<p><strong>Background: </strong>Ascaris lumbricoides is the most common helminthic infection. More than 1.2 billion people have ascariasis worldwide.</p><p><strong>Objective: </strong>This article aimed to provide an update on the evaluation, diagnosis, and treatment of ascariasis.</p><p><strong>Methods: </strong>A PubMed search was conducted in February 2020 in Clinical Queries using the key terms \"ascariasis\" OR \"Ascaris lumbricoides\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews published within the past 10 years. The search was restricted to English literature. The information retrieved from the above search was used in the compilation of the present article. Patents were searched using the key term \"ascariasis\" OR \"Ascaris lumbricoides\" in www.freepatentsonline.com.</p><p><strong>Results: </strong>Ascaris lumbricoides is transmitted through the ingestion of embryonated eggs from fecal- contaminated material. Ascariasis has high endemicity in tropical and subtropical areas. Predisposing factors include poverty, poor sanitation, inadequate sewage disposal, and poor personal hygiene. The prevalence is greatest in children younger than 5 years of age. The majority of patients with intestinal ascariasis are asymptomatic. For those with symptoms, anorexia, nausea, bloating, abdominal discomfort, recurrent abdominal pain, abdominal distension, and intermittent diarrhea are not uncommon. Other clinical manifestations vary widely, depending on the underlying complications. Complications include Löeffler syndrome, intestinal obstruction, biliary colic, recurrent pyogenic cholangitis, cholecystitis, acalculous cholecystitis, obstructive jaundice, cholelithiasis, pancreatitis, and malnutrition. The diagnosis is best established by microscopic examination of fecal smears or following concentration techniques for the characteristic ova. Patients with A. lumbricoides infection warrant anthelminthic treatment, even if they are asymptomatic, to prevent complications from migration of the parasite. Albendazole and mebendazole are the drugs of choice for children and nonpregnant individuals with ascariasis. Pregnant women with ascariasis should be treated with pyrantel pamoate. Recent patents related to the management of ascariasis are also discussed.</p><p><strong>Conclusion: </strong>The average cure rate with anthelminthic treatment is over 95%. Unfortunately, most treated patients in endemic areas become re-infected within months. Health education, personal hygiene, improved sanitary conditions, proper disposal of human excreta, and discontinuing the use of human fecal matter as a fertilizer are effective long-term preventive measures. Targeting deworming treatment and mass anthelminthic treatment should be considered in regions where A. lumbricoides is prevalent.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"133-145"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38128398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Meet Our Editorial Board Member 见见我们的编辑委员会成员
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-12-04 DOI: 10.2174/1872213x1302191122123948
A. Papi
{"title":"Meet Our Editorial Board Member","authors":"A. Papi","doi":"10.2174/1872213x1302191122123948","DOIUrl":"https://doi.org/10.2174/1872213x1302191122123948","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213x1302191122123948","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45807506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural Moieties as Anti-Inflammatory Agents-Recent Patents. 天然成分作为抗炎剂-最新专利。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-12-04 DOI: 10.2174/1872213x1302191122124225
H. Tuli, Ajay Sharma, A. Thakur
{"title":"Natural Moieties as Anti-Inflammatory Agents-Recent Patents.","authors":"H. Tuli, Ajay Sharma, A. Thakur","doi":"10.2174/1872213x1302191122124225","DOIUrl":"https://doi.org/10.2174/1872213x1302191122124225","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"13 2 1","pages":"83"},"PeriodicalIF":4.2,"publicationDate":"2019-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213x1302191122124225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44458151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets. 体外循环后的炎症反应和内皮功能障碍:病理生理学和药理学靶点。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-09-30 DOI: 10.2174/1872213X13666190724112644
O. Giacinto, U. Satriano, A. Nenna, C. Spadaccio, M. Lusini, C. Mastroianni, F. Nappi, M. Chello
BACKGROUNDEndothelial injury occurring during cardiopulmonary bypass is a major contributing factor in the development of organ dysfunction, which leads to many of the postoperative complications occurring during cardiac surgery.OBJECTIVEThis narrative review aims to summarize the main mechanisms of cardiopulmonary bypass - related disease, evaluating the unfavorable events leading to tissue injury, with a description of current pharmacologic and non-pharmacologic mechanisms to reduce CPB-related injury.METHODSA Medline/Pubmed/Scopus search was conducted using clinical queries with the key terms "cardiac surgery", "cardiopulmonary bypass", "inflammation" and "endothelial injury", and related MeSH terms, until July 2019. The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the same key terms from https://patents.google.com/, www.uspto.gov, and www.freepatentsonline.com.RESULTSIn this review we discuss the current knowledge of the mechanisms of vascular endothelial cell injury, the acute inflammatory response, and the regulatory factors that control the extent of vascular injury during extracorporeal circulation, summarizing the main target of anti-inflammatory pharmacologic and non-pharmacologic strategies.CONCLUSIONInflammatory response and endothelial dysfunction following cardiopulmonary bypass are the price to pay for the benefits offered during cardiac surgery procedures. Counteracting the detrimental effect of extracorporeal circulation appears to be crucial to improve clinical outcomes in pediatric and adult cardiac surgery. The intrinsic complexity and the tight interplay of the factors involved might require a holistic approach against inflammation and endothelial response.
背景:体外循环过程中发生的血管内皮损伤是器官功能障碍的一个重要因素,器官功能障碍导致心脏手术过程中出现许多术后并发症。目的综述体外循环相关疾病的主要机制,评价导致组织损伤的不良事件,并介绍目前体外循环相关损伤的药物和非药物机制。方法采用Medline/Pubmed/Scopus检索,检索关键词为“心脏外科”、“体外循环”、“炎症”和“内皮损伤”,以及相关MeSH术语,截止到2019年7月。检索策略包括荟萃分析、随机对照试验、临床试验、综述和相关参考文献。使用相同的关键词从https://patents.google.com/、www.uspto.gov和www.freepatentsonline.com.RESULTSIn检索专利。本文综述了血管内皮细胞损伤机制、急性炎症反应和体外循环过程中控制血管损伤程度的调节因子的最新知识,总结了抗炎药物和非药物策略的主要目标。结论体外循环术后的炎症反应和内皮功能障碍是心脏外科手术带来益处的代价。消除体外循环的不利影响似乎是改善儿科和成人心脏手术临床结果的关键。内在的复杂性和相关因素的紧密相互作用可能需要一个整体的方法来对抗炎症和内皮反应。
{"title":"Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets.","authors":"O. Giacinto, U. Satriano, A. Nenna, C. Spadaccio, M. Lusini, C. Mastroianni, F. Nappi, M. Chello","doi":"10.2174/1872213X13666190724112644","DOIUrl":"https://doi.org/10.2174/1872213X13666190724112644","url":null,"abstract":"BACKGROUND\u0000Endothelial injury occurring during cardiopulmonary bypass is a major contributing factor in the development of organ dysfunction, which leads to many of the postoperative complications occurring during cardiac surgery.\u0000\u0000\u0000OBJECTIVE\u0000This narrative review aims to summarize the main mechanisms of cardiopulmonary bypass - related disease, evaluating the unfavorable events leading to tissue injury, with a description of current pharmacologic and non-pharmacologic mechanisms to reduce CPB-related injury.\u0000\u0000\u0000METHODS\u0000A Medline/Pubmed/Scopus search was conducted using clinical queries with the key terms \"cardiac surgery\", \"cardiopulmonary bypass\", \"inflammation\" and \"endothelial injury\", and related MeSH terms, until July 2019. The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the same key terms from https://patents.google.com/, www.uspto.gov, and www.freepatentsonline.com.\u0000\u0000\u0000RESULTS\u0000In this review we discuss the current knowledge of the mechanisms of vascular endothelial cell injury, the acute inflammatory response, and the regulatory factors that control the extent of vascular injury during extracorporeal circulation, summarizing the main target of anti-inflammatory pharmacologic and non-pharmacologic strategies.\u0000\u0000\u0000CONCLUSION\u0000Inflammatory response and endothelial dysfunction following cardiopulmonary bypass are the price to pay for the benefits offered during cardiac surgery procedures. Counteracting the detrimental effect of extracorporeal circulation appears to be crucial to improve clinical outcomes in pediatric and adult cardiac surgery. The intrinsic complexity and the tight interplay of the factors involved might require a holistic approach against inflammation and endothelial response.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213X13666190724112644","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46294718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 56
Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature. 皮肤对全身使用的唑类抗真菌药物过敏:文献综述。
IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-09-30 DOI: 10.2174/1872213X13666190919162414
G. Calogiuri, L. H. Garvey, E. Nettis, P. Romita, E. Di Leo, R. Caruso, L. Butani, C. Foti
BACKGROUNDAntifungal azoles are the first-line agents used to treat topical and, above all, systemic mycosis. The latter could be life-threating infections in immunocompromised patients. Chemotherapeutic antibiotics, including antifungal azoles, may induce hypersensitivity reactions; however, such immunologic adverse reactions have not been as well defined and carefully investigated.OBJECTIVETo provide an update on the evaluation and diagnosis of skin allergy to azole antifungal agents.METHODSThis is a systematic review performed on PubMed and Google Schoolbarusing the key term "allergy, hypersensitivity, anaphylaxis, immediate-type reaction, delayed-type reaction, ketoconazole, fluconazole, posaconazole, voriconazole, itravuconazole, triazoles, imidazoles, antifungals, antimycotics"The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, reviews and case reports.RESULTSOne hundred twenty-four articles matched our search terms. The most common adverse events reported were T-cell mediateddelayed-type hypersensitivity reactions, such as fixed drug eruptions,localized, generalized and exhantematous dermatitis, Steven Johnson syndrome, toxic epidermal necrolysis and acute generalizedexhanthematouspustulosis. Rarely a drug rash, eosinophilia systemic symptoms has been described Also immediate-type reactions such as urticaria-angioedema or anaphylaxis have been reported following administration of antifungal imidazoles, although not so frequently.CONCLUSIONDespite their widespread use, triazoles seem to induce rare cutaneous hypersensitivity reactions, but the pathomechanisms, risk factors, diagnostic and management strategies, including skin tests and challenge tests, are little known and poorly investigated.
背景:抗真菌唑类药物是用于治疗局部和系统性真菌病的一线药物。后者可能是免疫功能低下患者的危及生命的感染。化疗抗生素,包括抗真菌唑类药物,可能会引起过敏反应;然而,这些免疫不良反应还没有被很好地定义和仔细地调查。目的探讨皮肤对唑类抗真菌药物过敏的诊断和评价。方法以“过敏、超敏反应、过敏反应、立即型反应、延迟型反应、酮康唑、氟康唑、泊沙康唑、伏立康唑、伊曲康唑、三唑类、咪唑类、抗真菌类、抗真菌类药物”为关键词,对PubMed和谷歌schoolbars进行系统综述。检索策略包括meta分析、随机对照试验、临床试验、观察性研究、综述和病例报告。结果124篇文章符合我们的搜索条件。最常见的不良反应是t细胞介导的延迟型超敏反应,如固定药疹、局部、全身性和外伤性皮炎、史蒂文·约翰逊综合征、中毒性表皮坏死松解和急性全身性外伤性口疱病。很少有药物皮疹,嗜酸性粒细胞增多的全体性症状也有报道,如荨麻疹-血管性水肿或过敏反应,在使用抗真菌咪唑后,尽管不常见。结论尽管三唑类药物被广泛使用,但其诱发皮肤过敏反应的机制、危险因素、诊断和治疗策略(包括皮肤试验和激发试验)知之甚少,研究也很少。
{"title":"Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature.","authors":"G. Calogiuri, L. H. Garvey, E. Nettis, P. Romita, E. Di Leo, R. Caruso, L. Butani, C. Foti","doi":"10.2174/1872213X13666190919162414","DOIUrl":"https://doi.org/10.2174/1872213X13666190919162414","url":null,"abstract":"BACKGROUND\u0000Antifungal azoles are the first-line agents used to treat topical and, above all, systemic mycosis. The latter could be life-threating infections in immunocompromised patients. Chemotherapeutic antibiotics, including antifungal azoles, may induce hypersensitivity reactions; however, such immunologic adverse reactions have not been as well defined and carefully investigated.\u0000\u0000\u0000OBJECTIVE\u0000To provide an update on the evaluation and diagnosis of skin allergy to azole antifungal agents.\u0000\u0000\u0000METHODS\u0000This is a systematic review performed on PubMed and Google Schoolbarusing the key term \"allergy, hypersensitivity, anaphylaxis, immediate-type reaction, delayed-type reaction, ketoconazole, fluconazole, posaconazole, voriconazole, itravuconazole, triazoles, imidazoles, antifungals, antimycotics\"The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, reviews and case reports.\u0000\u0000\u0000RESULTS\u0000One hundred twenty-four articles matched our search terms. The most common adverse events reported were T-cell mediateddelayed-type hypersensitivity reactions, such as fixed drug eruptions,localized, generalized and exhantematous dermatitis, Steven Johnson syndrome, toxic epidermal necrolysis and acute generalizedexhanthematouspustulosis. Rarely a drug rash, eosinophilia systemic symptoms has been described Also immediate-type reactions such as urticaria-angioedema or anaphylaxis have been reported following administration of antifungal imidazoles, although not so frequently.\u0000\u0000\u0000CONCLUSION\u0000Despite their widespread use, triazoles seem to induce rare cutaneous hypersensitivity reactions, but the pathomechanisms, risk factors, diagnostic and management strategies, including skin tests and challenge tests, are little known and poorly investigated.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213X13666190919162414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41974838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
期刊
Recent patents on inflammation & allergy drug discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1